1AD Stock Overview
A clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AdAlta Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.019 |
| 52 Week High | AU$0.041 |
| 52 Week Low | AU$0.016 |
| Beta | 0.61 |
| 11 Month Change | 0% |
| 3 Month Change | -13.64% |
| 1 Year Change | -5.00% |
| 33 Year Change | -77.38% |
| 5 Year Change | -84.17% |
| Change since IPO | -93.21% |
Recent News & Updates
Recent updates
Is AdAlta (ASX:1AD) A Risky Investment?
Oct 11
Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now
Nov 16Is AdAlta (ASX:1AD) Using Debt Sensibly?
Sep 02We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate
Jun 11Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth
Feb 26Shareholder Returns
| 1AD | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 5.6% | -3.6% | 1.5% |
| 1Y | -5.0% | 10.0% | 17.2% |
Return vs Industry: 1AD underperformed the Australian Biotechs industry which returned 9.8% over the past year.
Return vs Market: 1AD underperformed the Australian Market which returned 17.7% over the past year.
Price Volatility
| 1AD volatility | |
|---|---|
| 1AD Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: 1AD has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: 1AD's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 9 | Tim Oldham | www.adalta.com.au |
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. AdAlta Limited has collaborative partnerships with GE Healthcare Technologies Inc to develop i-body enabled PET imaging agents for use in immuno-oncology; and Carina Biotech Pty Ltd to develop CAR-T cell therapies for solid tumor.
AdAlta Limited Fundamentals Summary
| 1AD fundamental statistics | |
|---|---|
| Market cap | AU$11.52m |
| Earnings (TTM) | -AU$5.38m |
| Revenue (TTM) | AU$1.74m |
6.6x
P/S Ratio-2.1x
P/E RatioIs 1AD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1AD income statement (TTM) | |
|---|---|
| Revenue | AU$1.74m |
| Cost of Revenue | AU$229.88k |
| Gross Profit | AU$1.51m |
| Other Expenses | AU$6.89m |
| Earnings | -AU$5.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0089 |
| Gross Margin | 86.77% |
| Net Profit Margin | -309.66% |
| Debt/Equity Ratio | 128.3% |
How did 1AD perform over the long term?
See historical performance and comparison